The Global Clinical Research Service provider, Charles River Laboratories International CRL has seen a recent flurry of activity in the market. Notably, UBS Asset Management Americas LLC and Amundi offloaded significant shares of CRL, while Balefire LLC, Goldman Sachs Group Inc, and Royal Bank of Canada increased their holdings. Meanwhile, Eminence Capital LP and Fragasso Financial Advisors Inc reduced their stakes in CRL.
Despite some unfavorable short-term movement, CRL has established promising Oncology Partnerships with PICI and CHLA. Additionally, Baird maintained a neutral rating but increased the price target to $161 from $151. Relevant industry insiders like Wall Street Zen and Redburn have favored CRL with a 'Strong-Buy' and 'Buy' rating respectively. However, the company's CFO transition and insight into potential margin pressures have raised concerns among stakeholders.
Importantly, the firm reaffirms its Earnings Guidance for 2025, with its Q1 and Q2 2025 Earnings Calls featuring critical navigation strategies. The company has also reported progress in Cell Therapy collaborations and gene therapy development, reflecting its continuous strive towards innovation.
Charles River Laboratories International CRL News Analytics from Fri, 14 Feb 2025 08:00:00 GMT to Sat, 20 Sep 2025 16:03:19 GMT - Rating 3 - Innovation 6 - Information 8 - Rumor 2
